Plus therapeutics announces share repurchase program

Austin, texas, aug. 15, 2022 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that its board of directors has approved a share repurchase program with authorization to repurchase up to $2.0 million of the company's outstanding common stock. the company intends to fund any share repurchases with available cash.
PSTV Ratings Summary
PSTV Quant Ranking